jeudi 9 janvier 2020

Onco Actu du 9 janvier 2020


2.13 ETIOLOGIE - NDMA



FDA alerts patients and health care professionals to two voluntary recalls of ranitidine [FDA]











2.14 ETIOLOGIE - TALC



Relief for J&J? Large new study finds no clear link between talc and cancer [Fierce Pharma]











'No evidence' that talcum powder causes ovarian cancer new review finds [NHS Choices]










3.4 CHIMIOPRÉVENTION



Statins may do double duty on heart disease and cancer {AHA]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



AI can be used to detect and grade prostate cancer [Karolinska Institutet]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Nanoparticles Deliver ‘Suicide Gene’ Therapy to Pediatric Brain Tumors Growing in Mice [Johns Hopkins]











Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas [MD Anderson Cancer Center]











Two drugs used in combination prove to be effective against most aggressive asbestos cancer in mice [CNIO]











5.10 TRAITEMENTS - ESSAIS



For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge [NCI]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment [EndPoints]











Pancreatic Cancer Cells Secrete Signal that Sabotages Immune Attack on Tumors [NYU Langone Health]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Shreds of Tregs: French biotech wins Medicxi backing to kill the rogue immunosuppressive agent to fight cancer [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy [Merck]











Merck's Keytruda wins U.S. FDA approval for bladder cancer [Reuters]











FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer [FDA]










5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Lung cancer immunotherapy gets initial ‘no’ for NHS in England [Cancer Research UK]











5.2.1 PHARMA - PARTENARIATS



Scoop: Sanofi quietly ties up with a low-profile, preclinical cancer biotech — FTC signs off [EndPoints]











5.2.6 PHARMA - BIOTECH



Lilly looms over Blueprint as the biotech files targeted cancer drug [Biopharma Dive]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Fostering Oncology Product Development for Kids with Cancer [FDA Law Blog]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



2019 FDA drug approvals [Nature Reviews Drug Discovery]











6. LUTTE CONTRE LES CANCERS



Big News in Cancer, Versus Big Talk About It [In The Pipeline]










At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find [STAT]











6.1 OBSERVATION



Steepest decline in US cancer mortality ever recorded, study finds [EndPoints]










Strides in lung cancer lead steep decline in U.S. death rates [Reuters]











Immunotherapy, precision medicine in lung cancer drive sharp decline in cancer mortality overall [The Cancer Letter]










Facts & Figures 2020 Reports Largest One-year Drop in Cancer Mortality [ACS]











Cancer Death Rate in U.S. Sees Sharpest One-Year Drop [NY Times]